Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Lung Neoplasms 2Hematologic Neoplasms 2Gastrointestinal Stromal Tumors 2Advanced Malignancies 2Solid Tumor 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Melanoma 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1Carcinoma, Squamous Cell 1Carcinoma, Large Cell 1

Interventions

Carboplatin 3motexafin gadolinium 2figitumumab 2cemiplimab 2brigatinib 2alpha-2'-deoxythioguanosine 2Paclitaxel 2Docetaxel 2vandetanib 1tanespimycin 1Vinorelbine 1Temozolomide 1Pemetrexed 1Gemcitabine 1Everolimus 1Erlotinib Hydrochloride 1Crizotinib 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Large Cell × tanespimycin × Clear all
NCT01362400 2014-05-19

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Infinity Pharmaceuticals, Inc.

Phase 2 Completed
226 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡